Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma

4 Jan 2019

Abstract excerpt

Abstract Alterations in transcriptional programs promote tumor development and progression and are targetable by bromodomain and extraterminal (BET) protein inhibitors. However, in a multi‐site clinical trial testing the novel BET inhibitor, PLX51107, in solid cancer patients, liver metastases of uveal melanoma (UM) patients progressed rapidly following treatment. Mechanisms of resistance to BET inhibitors in UM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Ocular Oncology and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30610113
DOI: 10.15252/emmm.201809081

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanomaPMID 30610113Read ↗

Inhibition of NF-κB–Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal MelanomaSemantic proximity Read ↗

Highly expressed STING in liver metastasis of uveal melanoma can lead to synergistic killingSemantic proximity Read ↗

AURKB Enhances Chromosomal Remodeling of Telomeric Genes and Accelerates Tumorigenesis of Uveal MelanomaSemantic proximity Read ↗

Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal MelanomaSemantic proximity Read ↗

Decitabine limits escape from MEK inhibition in uveal melanomaSemantic proximity Read ↗

Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanomaSemantic proximity Read ↗

Uveal melanoma cell lines Mel270 and 92.1 exhibit a mesenchymal phenotype and sensitivity to the cytostatic effects of transforming growth factor beta in vitro.Semantic proximity Read ↗

Contribution of the STAT Family of Transcription Factors to the Expression of the Serotonin 2B (HTR2B) Receptor in Human Uveal MelanomaSemantic proximity Read ↗

Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.Semantic proximity Read ↗

Azacytidine treatment affects the methylation pattern of genomic and cell-free DNA in uveal melanoma cell linesSemantic proximity Read ↗

FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthaseSemantic proximity Read ↗

Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.